Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Eager To Establish Pharmacovigilance System – SFDA Officials

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - In an effort to ensure drug safety, China will establish a pharmacovigilance system and will continue to improve its adverse drug reaction reports system, said Yan Ming, director of the drug re-evaluation division under China's State FDA drug safety and inspection department, during an international conference on post-market drug safety Oct. 29 in Shanghai

You may also be interested in...



Pharmacovigilance Is A Global Safety Issue – DIA Singapore Conference

Pharmacovigilance and risk management is a global safety issue, and the quality of safety data that is being retrieved is more important than where the data is coming from, according to consultant and former U.S. FDA MedWatch Medical Director Stephen Goldman

Pharmacovigilance Is A Global Safety Issue – DIA Singapore Conference

Pharmacovigilance and risk management is a global safety issue, and the quality of safety data that is being retrieved is more important than where the data is coming from, according to consultant and former U.S. FDA MedWatch Medical Director Stephen Goldman

Focused On Globalization, Shanghai FDA Will Hold International Forum On Drug Safety And Regulatory Change

BEIJING - In an effort to fast-forward the globalization of China's drug laws and utlimately boost its exports of pharmaceuticals, the Shanghai FDA is partnering with a U.S.-based law firm to co-host its first international forum on drug safety and regulatory change

Related Content

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel